default author photo

Claudio Vernieri

Fondazione IRCCS Istituto Nazionale dei Tumori

Via Giacomo Venezian, 1

Milano MI, 20133

Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumori

SCHOLARLY PAPERS

5

DOWNLOADS

300

TOTAL CITATIONS

0

Scholarly Papers (5)

Actions:
Email selected abstracts
1.

Efficacy and Safety of Systemic Therapies Following Progression on CDK4/6 Inhibitors in Patients with HR+/HER2-- Metastatic Breast Cancer: A Systematic Review and Network Meta-Analysis

Number of pages: 35 Posted: 13 Jun 2025
Roberto Buonaiuto, Mario Fordellone, Aldo Caltavituro, Maria L. Cataldo, Carmen Criscitiello, Maria Vittoria Dieci, Matteo Lambertini, Andrea Botticelli, Mario Giuliano, Antonio Giordano, Federica P. Mangiacotti, Angela Grieco, Alessandra Longobardi, Roberta Caputo, Martina Pagliuca, Claudio Vernieri, Luca Malorni, Lorenzo Gerratana, Maria Grazia Arpino, Paolo Chiodini, Michelino De Laurentiis and Carmine De Angelis
Scuola Superiore Meridionale, Vanvitelli University of Campania Luigi Vanvitelli, University of Naples Federico II, Baylor College of Medicine, University of Milan, University of Padova, University of Genova - Department of Internal Medicine and Medical Specialties (DiMI), Sapienza University of Rome, Baylor College of Medicine, Harvard University - Dana-Farber Cancer Institute, University of Naples Federico II, University of Naples Federico II, University of Naples Federico II, Fondazione IRCCS Istituto Nazionale dei Tumori, Gustave Roussy, Fondazione IRCCS Istituto Nazionale dei Tumori, Azienda USL Toscana Centro - Sandro Pitigliani Translational Research Unit, University of Udine - Deparment of Medicine (DAME), University of Naples Federico II, Vanvitelli University of Campania Luigi Vanvitelli, IRCCS-Fondazione Bietti and Baylor College of Medicine
Downloads 146 (505,974)

Abstract:

Loading...

HR+/HER2- metastatic breast cancer, CDK4/6 inhibitor resistance, Systematic Review, Network meta-analysis, Biomarker-driven therapy, Antibody-drug conjugates

2.

Adjuvant Ovarian Function Suppression and Aromatase Inhibitors in Premenopausal Patients with Hormone Receptor And Her2 Positive Breast Cancer, by Timing of Chemotherapy and Trastuzumab and Response to Neoadjuvant Therapy

Number of pages: 22 Posted: 16 Jul 2025
Ayelet Shai, Hans Wildiers, Claudio Vernieri, Katarzyna Pogoda, Barbro Linderholm, Matteo Lambertini, Leonor Matos, Eleonora De Maio D’Esposito, Nawale Hajjaji, Erika Matos, Lucia Gonzalez-Cortijo, Giuseppe Fotia, Ana Fortuna, Tal Sella, Helena Gouveia, Laurent Rosset, Anastasia Constantinidou, Eurydice Angeli, Irfan Cicin, Vivianne C.G. Tjan-Heijnen, Natacha Ruyssers, Sofie Demasure, Areen Abu Remilah, Greet Huygh, Shani Paluch-Shimon, Edoardo Chiappe, Natali Shirron, Patrick Neven, Mehmet Artac, Bilgesah Kilictas, Jalal Baranseh, Elena Vicente-Rubio, Mustafa Atci, Ottavia Amato and Frederieke van Duijnhoven
Technion-Israel Institute of Technology - Rambam Health Care Campus, KU Leuven - University Hospitals Leuven, Fondazione IRCCS Istituto Nazionale dei Tumori, affiliation not provided to SSRN, University of Gothenburg - Sahlgrenska University Hospital, University of Genova - Department of Internal Medicine and Medical Specialties (DiMI), affiliation not provided to SSRN, affiliation not provided to SSRN, Université de Lille - Protéomique Réponse Inflammatoire Spectrométrie de Masse - PRISM, Institute of Oncology, affiliation not provided to SSRN, Fondazione IRCCS Istituto Nazionale dei Tumori, Santa Maria Local Health Unit, affiliation not provided to SSRN, affiliation not provided to SSRN, HFR Fribourg Cantonal Hospital, Bank of Cyprus Oncology Centre, Institut National de la Santé et de la Recherche Médicale (INSERM), Istinye University, Maastricht University, AZ Turnhout, AZ Groeninge, Hebrew University of Jerusalem - Shaare Zedek Medical Center, affiliation not provided to SSRN, Hebrew University of Jerusalem - The Sharett Institute of Oncology, IRCCS Ospedale Policlinico San Martino, Technion-Israel Institute of Technology - Rambam Health Care Campus, KU Leuven - Department of Gynecologic Oncology, affiliation not provided to SSRN, affiliation not provided to SSRN, Technion-Israel Institute of Technology - Rambam Health Care Campus, affiliation not provided to SSRN, Istinye University, European Commission, Joint Research Centre and Netherlands Cancer Institute
Downloads 52 (1,041,696)

Abstract:

Loading...

Ovarian function suppression, HER2 positive, adjuvant endocrine therapy, aromatase inhibitors, tamoxifen, LHRH agonists, neoadjuvant, residual disease, pathological complete response

3.

Insights on the Association of Anthropometric and Metabolic Variables with Tumor Features and Genomic Risk in Luminal Early Breast Cancer: Results of a Multicentric Prospective Study

Number of pages: 23 Posted: 04 Mar 2025
Pietro De Placido, Rossana Di Rienzo, Erica Pietroluongo, Claudia Martinelli, Margherita Tafuro, Pietro Formisano, Vittoria D’Esposito, Francesca Poggio, Tommaso Ruelle, Barbara Cardinali, Vincenzo Di Lauro, Giuseppe Buono, Roberta Caputo, Roberto Buonaiuto, Aldo Caltavituro, Paola Rocco, Giuseppe Porciello, Michelino De Laurentiis, Lucia Del Mastro, Claudio Vernieri, Bianca Maria Veneziani, Roberto Bianco, Anna Crispo, Carmine De Angelis, Maria Grazia Arpino and Mario Giuliano
Harvard University - Dana-Farber Cancer Institute, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Naples Federico II, Fondazione IRCCS Istituto Nazionale dei Tumori, affiliation not provided to SSRN, University of Naples Federico II, affiliation not provided to SSRN, IRCCS Ospedale Policlinico San Martino, IRCCS Ospedale Policlinico San Martino, IRCCS Ospedale Policlinico San Martino, University of Naples Federico II, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Scuola Superiore Meridionale, University of Naples Federico II, Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale, Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale, IRCCS-Fondazione Bietti, University of Genova - Department of Internal Medicine and Medical Specialties (DiMI), Fondazione IRCCS Istituto Nazionale dei Tumori, University of Naples Federico II, University of Naples Federico II, Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale, Baylor College of Medicine, University of Naples Federico II and University of Naples Federico II
Downloads 37 (1,222,651)

Abstract:

Loading...

Breast Neoplasms, Recurrence Score, Obesity, Tumor Size, Body Mass Index, Glucagon-Like Peptide 1

4.

Health-related quality of life and fear of recurrence after early breast cancer treatment: results from a cross-sectional survey

Number of pages: 25 Posted: 04 Sep 2025
Paola Mosconi, Secondo Folli, Rosalba Miceli, Serena Scrudato, Massimiliano Gennaro, Gabriele Tinè, Maria Carmen De Santis, Cristina Ferraris, Gabriele Martelli, Immacolata Di Carlo, Ilaria Maugeri, Alessio Arata, Maria Grazia Carnevale, Chiara Listorti, Roberto Agresti, Claudia Borreani, Claudio Vernieri, Giancarlo Pruneri, Serena Di Cosimo, Valentina Appierto and Giovanni Apolone
affiliation not provided to SSRN, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, affiliation not provided to SSRN, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, affiliation not provided to SSRN, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori and Fondazione IRCCS Istituto Nazionale dei Tumori
Downloads 35 (1,249,711)

Abstract:

Loading...

Breast cancer survivors, follow-up, quality of life, fear of cancer recurrence, socio-economic status.

5.

Development of a machine learning model to guide further metastatic biopsy decision in patients with HER2-0 status on both primary breast cancer and first biopsied metastatic site: who should undergo a repeated biopsy to detect HER2-low gain?

Downloads 30 (1,318,317)

Development of a machine learning model to guide further metastatic biopsy decision in patients with HER2-0 status on both primary breast cancer and first biopsied metastatic site: who should undergo a repeated biopsy to detect HER2-low gain?

Number of pages: 17 Posted: 12 Jan 2026
Federica Miglietta, Antonio Collesei, Claudio Vernieri, Tommaso Giarratano, Carlo Alberto Giorgi, Fabio Girardi, Gaia Griguolo, Matilde Cacciatore, Federico Piacentini, Andrea Botticelli, Andrea Vingiani, Lorenzo Casadei, Giuseppe Fotia, Davide Massa, Pietro Napolitano, Giusy Landa, Dario Palleschi, Giancarlo Pruneri, Rocco Cappellesso, Angelo Paolo Dei Tos, Maria Vittoria Dieci and Valentina Guarneri
affiliation not provided to SSRN, affiliation not provided to SSRN, Fondazione IRCCS Istituto Nazionale dei Tumori, affiliation not provided to SSRN, affiliation not provided to SSRN, London School of Hygiene & Tropical Medicine - Cancer Survival Group, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Sapienza University of Rome, Fondazione IRCCS Istituto Nazionale dei Tumori, affiliation not provided to SSRN, Fondazione IRCCS Istituto Nazionale dei Tumori, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Fondazione IRCCS Istituto Nazionale dei Tumori, affiliation not provided to SSRN, University of Padua - Department of Medicine, Università di Padova - Dipartimento di Scienze Chirurgiche and affiliation not provided to SSRN
Downloads 19 (1,513,226)

Abstract:

Loading...

Breast Cancer, HER2-low, machine-learning

Development of a machine learning model to guide further metastatic biopsy decision in patients with HER2-0 status on both primary breast cancer and first biopsied metastatic site: who should undergo a repeated biopsy to detect HER2-low gain?

Number of pages: 17 Posted: 14 Jan 2026
Federica Miglietta, Antonio Collesei, Claudio Vernieri, Tommaso Giarratano, Carlo Alberto Giorgi, Fabio Girardi, Gaia Griguolo, Matilde Cacciatore, Federico Piacentini, Andrea Botticelli, Andrea Vingiani, Lorenzo Casadei, Giuseppe Fotia, Davide Massa, Pietro Napolitano, Giusy Landa, Dario Palleschi, Giancarlo Pruneri, Rocco Cappellesso, Angelo Paolo Dei Tos, Maria Vittoria Dieci and Valentina Guarneri
affiliation not provided to SSRN, affiliation not provided to SSRN, Fondazione IRCCS Istituto Nazionale dei Tumori, affiliation not provided to SSRN, affiliation not provided to SSRN, London School of Hygiene & Tropical Medicine - Cancer Survival Group, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Sapienza University of Rome, Fondazione IRCCS Istituto Nazionale dei Tumori, affiliation not provided to SSRN, Fondazione IRCCS Istituto Nazionale dei Tumori, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Fondazione IRCCS Istituto Nazionale dei Tumori, affiliation not provided to SSRN, University of Padua - Department of Medicine, Università di Padova - Dipartimento di Scienze Chirurgiche and affiliation not provided to SSRN
Downloads 11 (1,598,105)

Abstract:

Loading...

breast cancer, HER2-low, machine-learning